Picture loading failed.

Anti-IL5 therapeutic antibody (Pre-made Mepolizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES). It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-341-1mg 1mg 3090
GMP-Bios-ab-341-10mg 10mg 21890
GMP-Bios-ab-341-100mg 100mg 148000
GMP-Bios-ab-341-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-IL5 therapeutic antibody (Pre-made Mepolizumab biosimilar,Whole mAb)
INN Name Mepolizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed1999
Year Recommended2000
CompaniesGlaxoSmithKline;McMaster University;National Institute of Allergy and Infectious Diseases
Conditions ApprovedAsthma;Churg-Strauss syndrome;Hypereosinophilic syndrome
Conditions ActiveChronic obstructive pulmonary disease;Hypereosinophilic syndrome;Nasal polyps;Eosinophilic oesophagitis
Conditions DiscontinuedAtopic dermatitis
Development Techna